

Global Radiotheranostics Market By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others), By Application (Oncology v/s Non-Oncology), By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others) and By Region, Competition Forecast and Opportunities, 2027

Market Report | 2022-10-01 | 118 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License \$4900.00
- Multi-User License \$5900.00
- Custom Research License \$8900.00

Report description:

Global radiotheranostics market is anticipated to register growth at an impressive CAGR in the forecast period, 2023-2027. Radiotheranostics is a process that involves the use of radionuclides for paired imaging and therapy agents. It is a systematic integration of targeted diagnostics and therapeutics. The growing prevalence of cancer and the rising adoption of injectable radiopharmaceuticals that have antitumor effects are majorly contributing to the global radiotheranostics market growth. The increasing usage of radiotheranostics in cancer diagnosis and management is providing a thrust to the market. Radiotheranostics have enhanced therapy efficacy, the ability to manage adverse and critical health situations, which results in improved patient outcomes.

Moreover, the recent research and developments in the radiotheranostics field is creating a positive impact on the market growth. For instance, there have been major outcomes in radiotheranostics for prostate cancer and neuroendocrine tumors. Additionally, the regulatory approval of numerous radiotheranostics pairs is expected to boost their adoption for cancer treatments. For instance, the approvals of new radiotheranostics agents such as 177Lu-PSMA-617 and 177Lu-DOTATATE have resulted in the resurgence of research in the field of radiotheranostics and have proliferated the number of clinical trials and testing several other novel radiotheranostics. Furthermore, the continuous support in research and development to keep pace with current momentum in radiotheranostics innovations is supporting the market growth. Additionally, the clinical use of radiotheranostics agents have increased dramatically due to the successful strides that have been made in the understanding of underlying biology of cancer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

and enhanced methods for synthesizing and designing targeted theragnostic agents. This, in turn, is positively influencing the market growth.

Structural imaging is the most crucial component of staging, diagnosing, and assessing responses in cancer patients. However, patients and healthcare professionals are increasingly seeking non-invasive methods of investigating tumor phenotypes and assessing molecular and functional responses to therapy. Therefore, radiotheranostics, a combination of non-invasive diagnostic imaging with targeted therapy, is widely being implemented. As a result, the global market for radiotheranostics is anticipated to propel at a rapid pace in the coming years.

Market Segmentation

The global radiotheranostics market is segmented by radioisotope, application, end user, competitive landscape, and regional distribution. Based on the radioisotope, the market is differentiated between technetium-99, gallium-68, iodine-131, iodine-123, 18f, y-90, lutetium (lu) 177, copper (cu) 67, copper (cu) 64, and others. By offering the market is fragmented between oncology and non-oncology. The oncology segment is further bifurcated into thyroid cancer, neuroendocrine cancer, hepatocellular carcinoma, multiple myeloma and lymphoma, and other. The non-oncology application segment is further divided between joint infections, arthritis, bone pain, and others. On the basis of end user, the global market is segmented between hospitals & clinics, pharmaceutical & biotechnology companies, and others. The market analysis also studies the regional segmentation to devise regional market segmentation, divided among North America, Europe, Asia Pacific, Middle east and Africa, South America.

Company Profile

TransCode Therapeutics, Inc., Curium SAS, GE Healthcare Inc., Bayer AG, Lantheus Medical, Imaging, Inc., Novartis AG, Spectrum Pharmaceuticals, Inc., Ipsen S.A., Actinium Pharmaceuticals, Inc. (ATNM), Nordic Nanovector ASA, Y-mAbs Therapeutics, Inc., Sofie Biosciences, Inc., Terumo Corporation, Sirtex Medical Limited, and Boston Scientific Corporation are the leading market players responsible for the growth of global radiotheranostics market.

Report Scope:

In this report, global radiotheranostics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

- Global Radiotheranostics Market, By Radioisotope:

- o Technetium-99
- o Gallium-68
- o Iodine-131
- o Iodine-123
- o 18F
- o Y-90
- o Lutetium (Lu) 177
- o Copper (Cu) 67
- o Copper (Cu) 64
- o Others

- Global Radiotheranostics Market, By Application:

- o Oncology
 - Thyroid Cancer
 - Neuroendocrine Cancer
 - Hepatocellular Carcinoma
 - Multiple Myeloma

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Lymphoma, Others
 - o□Non-Oncology
- Joint Infections
- Arthritis
- Bone Pain
- Others
- Global Radiotheranostics Market, By End User:
 - o□Hospitals & Clinics
 - o□Pharmaceutical & Biotechnology Companies
 - o□Others
- Global Radiotheranostics Market, By Region:
 - o□North America
 - United States
 - Mexico
 - Canada
 - o□Europe
 - France
 - Germany
 - United Kingdom
 - Italy
 - Spain
 - o□Asia Pacific
 - China
 - India
 - South Korea
 - Japan
 - Australia
 - o□Middle East and Africa
 - South Africa
 - Saudi Arabia
 - UAE
 - o□South America
 - Brazil
 - Argentina
 - Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global radiotheranostics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

- Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

- 1.□Product Overview
- 2.□Research Methodology
- 3.□Executive Summary

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

4. Impact of COVID-19 on Global Radiotheranostics Market
5. Voice of Customer
 - 5.1. Radiotheranostics Awareness
 - 5.2. Cancer Prevalence, By Gender
 - 5.3. Cancer Prevalence, By Age Group
 - 5.4. Cancer Prevalence, Region
 - 5.5. Benefits of Using Radiotheranostics
6. Clinical Trial Analysis
7. Patent Analysis
8. Global Radiotheranostics Market Outlook
 - 8.1. Market Size & Forecast
 - 8.1.1. By Value
 - 8.2. Market Share & Forecast
 - 8.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
 - 8.2.2. By Application (Oncology v/s Non-Oncology)
 - 8.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
 - 8.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
 - 8.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
 - 8.2.4. By Region
 - 8.2.5. By Company (2021)
 - 8.3. Product Market Map
9. North America Radiotheranostics Market Outlook
 - 9.1. Market Size & Forecast
 - 9.1.1. By Value
 - 9.2. Market Share & Forecast
 - 9.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
 - 9.2.2. By Application (Oncology v/s Non-Oncology)
 - 9.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
 - 9.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
 - 9.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
 - 9.2.4. By Country
 - 9.3. North America: Country Analysis
 - 9.3.1. United States Radiotheranostics Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Radioisotope
 - 9.3.1.2.2. By Application
 - 9.3.1.2.3. By End User
 - 9.3.2. Mexico Radiotheranostics Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.3.2.2.1. By Radioisotope
- 9.3.2.2.2. By Application
- 9.3.2.2.3. By End User
- 9.3.3. Canada Radiotheranostics Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Radioisotope
- 9.3.3.2.2. By Application
- 9.3.3.2.3. By End User
- 10. Europe Radiotheranostics Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
- 10.2.2. By Application (Oncology v/s Non-Oncology)
- 10.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
- 10.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
- 10.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
- 10.2.4. By Country
- 10.3. Europe: Country Analysis
- 10.3.1. France Radiotheranostics Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Radioisotope
- 10.3.1.2.2. By Application
- 10.3.1.2.3. By End User
- 10.3.2. Germany Radiotheranostics Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Radioisotope
- 10.3.2.2.2. By Application
- 10.3.2.2.3. By End User
- 10.3.3. United Kingdom Radiotheranostics Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Radioisotope
- 10.3.3.2.2. By Application
- 10.3.3.2.3. By End User
- 10.3.4. Italy Radiotheranostics Market Outlook
- 10.3.4.1. Market Size & Forecast
- 10.3.4.1.1. By Value

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.3.4.2.□Market Share & Forecast
 - 10.3.4.2.1.□By Radioisotope
 - 10.3.4.2.2.□By Application
 - 10.3.4.2.3.□By End User
- 10.3.5.□Spain Radiotheranostics Market Outlook
 - 10.3.5.1.□Market Size & Forecast
 - 10.3.5.1.1.□By Value
 - 10.3.5.2.□Market Share & Forecast
 - 10.3.5.2.1.□By Radioisotope
 - 10.3.5.2.2.□By Application
 - 10.3.5.2.3.□By End User
- 11.□Asia-Pacific Radiotheranostics Market Outlook
 - 11.1.□Market Size & Forecast□
 - 11.1.1.□By Value
 - 11.2.□Market Share & Forecast
 - 11.2.1.□By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
 - 11.2.2.□By Application (Oncology v/s Non-Oncology)
 - 11.2.2.1.□Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
 - 11.2.2.2.□Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
 - 11.2.3.□By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
 - 11.2.4.□By Country
 - 11.3.□Asia-Pacific: Country Analysis
 - 11.3.1.□China Radiotheranostics Market Outlook
 - 11.3.1.1.□Market Size & Forecast
 - 11.3.1.1.1.□By Value
 - 11.3.1.2.□Market Share & Forecast
 - 11.3.1.2.1.□By Radioisotope
 - 11.3.1.2.2.□By Application
 - 11.3.1.2.3.□By End User
 - 11.3.2.□India Radiotheranostics Market Outlook
 - 11.3.2.1.□Market Size & Forecast
 - 11.3.2.1.1.□By Value
 - 11.3.2.2.□Market Share & Forecast
 - 11.3.2.2.1.□By Radioisotope
 - 11.3.2.2.2.□By Application
 - 11.3.2.2.3.□By End User
 - 11.3.3.□South Korea Radiotheranostics Market Outlook
 - 11.3.3.1.□Market Size & Forecast
 - 11.3.3.1.1.□By Value
 - 11.3.3.2.□Market Share & Forecast
 - 11.3.3.2.1.□By Radioisotope
 - 11.3.3.2.2.□By Application
 - 11.3.3.2.3.□By End User
 - 11.3.4.□Japan Radiotheranostics Market Outlook
 - 11.3.4.1.□Market Size & Forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.3.4.1.1. By Value
- 11.3.4.2. Market Share & Forecast
- 11.3.4.2.1. By Radioisotope
- 11.3.4.2.2. By Application
- 11.3.4.2.3. By End User
- 11.3.5. Australia Radiotheranostics Market Outlook
- 11.3.5.1. Market Size & Forecast
- 11.3.5.1.1. By Value
- 11.3.5.2. Market Share & Forecast
- 11.3.5.2.1. By Radioisotope
- 11.3.5.2.2. By Application
- 11.3.5.2.3. By End User
- 12. South America Radiotheranostics Market Outlook
- 12.1. Market Size & Forecast
- 12.1.1. By Value
- 12.2. Market Share & Forecast
- 12.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
- 12.2.2. By Application (Oncology v/s Non-Oncology)
- 12.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
- 12.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
- 12.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
- 12.2.4. By Country
- 12.3. South America: Country Analysis
- 12.3.1. Brazil Radiotheranostics Market Outlook
- 12.3.1.1. Market Size & Forecast
- 12.3.1.1.1. By Value
- 12.3.1.1.2. Market Share & Forecast
- 12.3.1.1.2.1. By Radioisotope
- 12.3.1.1.2.2. By Application
- 12.3.1.1.2.3. By End User
- 12.3.1.2. Argentina Radiotheranostics Market Outlook
- 12.3.1.2.1. Market Size & Forecast
- 12.3.1.2.1.1. By Value
- 12.3.1.2.2. Market Share & Forecast
- 12.3.1.2.2.1. By Radioisotope
- 12.3.1.2.2.2. By Application
- 12.3.1.2.2.3. By End User
- 12.3.2. Colombia Radiotheranostics Market Outlook
- 12.3.2.1. Market Size & Forecast
- 12.3.2.1.1. By Value
- 12.3.2.2. Market Share & Forecast
- 12.3.2.2.1. By Radioisotope
- 12.3.2.2.2. By Application
- 12.3.2.2.3. By End User
- 12.3.3. Middle East and Africa Radiotheranostics Market Outlook

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.1. Market Size & Forecast
 - 13.1.1. By Value
- 13.2. Market Share & Forecast
 - 13.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
 - 13.2.2. By Application (Oncology v/s Non-Oncology)
 - 13.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
 - 13.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
 - 13.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
 - 13.2.4. By Country
- 13.3. MEA: Country Analysis
 - 13.3.1. South Africa Radiotheranostics Market Outlook
 - 13.3.1.1. Market Size & Forecast
 - 13.3.1.1.1. By Value
 - 13.3.1.2. Market Share & Forecast
 - 13.3.1.2.1. By Radioisotope
 - 13.3.1.2.2. By Application
 - 13.3.1.2.3. By End User
 - 13.3.2. Saudi Arabia Radiotheranostics Market Outlook
 - 13.3.2.1. Market Size & Forecast
 - 13.3.2.1.1. By Value
 - 13.3.2.2. Market Share & Forecast
 - 13.3.2.2.1. By Radioisotope
 - 13.3.2.2.2. By Application
 - 13.3.2.2.3. By End User
 - 13.3.3. UAE Radiotheranostics Market Outlook
 - 13.3.3.1. Market Size & Forecast
 - 13.3.3.1.1. By Value
 - 13.3.3.2. Market Share & Forecast
 - 13.3.3.2.1. By Radioisotope
 - 13.3.3.2.2. By Application
 - 13.3.3.2.3. By End User
- 14. Market Dynamics
 - 14.1. Drivers
 - 14.2. Challenges
- 15. Market Trends & Developments
- 16. SWOT Analysis: Global Radiotheranostics Market
- 17. Competitive Landscape (Inclusive of SWOT Analysis of Players Profiled)
 - 17.1. TransCode Therapeutics, Inc.
 - 17.2. Curium SAS
 - 17.3. GE Healthcare Inc.
 - 17.4. Bayer AG
 - 17.5. Lantheus Medical Imaging, Inc.
 - 17.6. Novartis AG
 - 17.7. Spectrum Pharmaceuticals, Inc.
 - 17.8. Ipsen S.A.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

17.9. □ Actinium Pharmaceuticals, Inc. (ATNM)

17.10. □ Nordic Nanovector ASA

17.11. □ Y-mAbs Therapeutics, Inc.

17.12. □ Sofie Biosciences, Inc.

17.13. □ Terumo Corporation

17.14. □ Sirtex Medical Limited

17.15. □ Boston Scientific Corporation

18. □ Strategic Recommendations

(Note: The companies list can be customized based on the client requirements.)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Radiotheranostics Market By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others), By Application (Oncology v/s Non-Oncology), By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others) and By Region, Competition Forecast and Opportunities, 2027

Market Report | 2022-10-01 | 118 pages | TechSci Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4900.00
	Multi-User License	\$5900.00
	Custom Research License	\$8900.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-25"/>
		Signature	<input type="text"/>